Bildkälla: Stockfoto

Xspray Pharma: CRL – FDA requiring additional information - Redeye

Redeye expresses disappointment following this morning's news that Xspray has received a CRL for its NDA. We provide our comments and lower our base case as we await further information on how it will affect the timeline.

Redeye expresses disappointment following this morning's news that Xspray has received a CRL for its NDA. We provide our comments and lower our base case as we await further information on how it will affect the timeline.
Börsvärldens nyhetsbrev
ANNONSER